ATE141514T1 - Verfahren zur verhütung, stabilisierung oder verursachung des zurückgangs von atherosklerose durch anwendung einer mischung von einem cholesterol-vermindernden arzneimittel mit einem ace-inhibitor - Google Patents
Verfahren zur verhütung, stabilisierung oder verursachung des zurückgangs von atherosklerose durch anwendung einer mischung von einem cholesterol-vermindernden arzneimittel mit einem ace-inhibitorInfo
- Publication number
- ATE141514T1 ATE141514T1 AT91304232T AT91304232T ATE141514T1 AT E141514 T1 ATE141514 T1 AT E141514T1 AT 91304232 T AT91304232 T AT 91304232T AT 91304232 T AT91304232 T AT 91304232T AT E141514 T1 ATE141514 T1 AT E141514T1
- Authority
- AT
- Austria
- Prior art keywords
- atherosclerosis
- cholesterol
- ace inhibitor
- stabilizing
- preventing
- Prior art date
Links
- 239000005541 ACE inhibitor Substances 0.000 title abstract 2
- 201000001320 Atherosclerosis Diseases 0.000 title abstract 2
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 title abstract 2
- 239000003529 anticholesteremic agent Substances 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title 1
- 230000000087 stabilizing effect Effects 0.000 title 1
- 206010020772 Hypertension Diseases 0.000 abstract 1
- TUZYXOIXSAXUGO-UHFFFAOYSA-N Pravastatin Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21 TUZYXOIXSAXUGO-UHFFFAOYSA-N 0.000 abstract 1
- 230000003143 atherosclerotic effect Effects 0.000 abstract 1
- 229960000830 captopril Drugs 0.000 abstract 1
- FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 abstract 1
- 230000001631 hypertensive effect Effects 0.000 abstract 1
- 230000003902 lesion Effects 0.000 abstract 1
- TUZYXOIXSAXUGO-PZAWKZKUSA-N pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 abstract 1
- 229960002965 pravastatin Drugs 0.000 abstract 1
- 125000003396 thiol group Chemical group [H]S* 0.000 abstract 1
- 229960002769 zofenopril Drugs 0.000 abstract 1
- IAIDUHCBNLFXEF-MNEFBYGVSA-N zofenopril Chemical compound C([C@@H](C)C(=O)N1[C@@H](C[C@@H](C1)SC=1C=CC=CC=1)C(O)=O)SC(=O)C1=CC=CC=C1 IAIDUHCBNLFXEF-MNEFBYGVSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US52426690A | 1990-05-15 | 1990-05-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE141514T1 true ATE141514T1 (de) | 1996-09-15 |
Family
ID=24088484
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT91304232T ATE141514T1 (de) | 1990-05-15 | 1991-05-10 | Verfahren zur verhütung, stabilisierung oder verursachung des zurückgangs von atherosklerose durch anwendung einer mischung von einem cholesterol-vermindernden arzneimittel mit einem ace-inhibitor |
Country Status (15)
| Country | Link |
|---|---|
| EP (1) | EP0457514B1 (de) |
| JP (1) | JPH04226921A (de) |
| KR (1) | KR100200467B1 (de) |
| AT (1) | ATE141514T1 (de) |
| AU (1) | AU651579B2 (de) |
| CA (1) | CA2040865C (de) |
| DE (1) | DE69121464T2 (de) |
| DK (1) | DK0457514T3 (de) |
| ES (1) | ES2090244T3 (de) |
| GR (1) | GR3021703T3 (de) |
| HU (1) | HU212102B (de) |
| IE (1) | IE77637B1 (de) |
| NZ (1) | NZ237929A (de) |
| PT (1) | PT97660B (de) |
| ZA (1) | ZA913509B (de) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5157025A (en) * | 1991-04-01 | 1992-10-20 | E. R. Squibb & Sons, Inc. | Method for lowering serum cholesterol employing a phosphorus containing ace inhibitor alone or in combination with a cholesterol lowering drug |
| AU3473193A (en) * | 1992-01-17 | 1993-08-03 | Procter & Gamble Company, The | Treatment for atherosclerosis |
| AU1095695A (en) * | 1993-11-09 | 1995-05-29 | Brigham And Women's Hospital | Hmg-coa reductase inhibitors in the normalization of vascular endothelial dysfunction |
| DE4402379C2 (de) * | 1994-01-27 | 1997-09-25 | Lohmann Therapie Syst Lts | Orale Arzneiform mit sauren Wirkstoffen und Verfahren zu ihrer Herstellung |
| CA2186606A1 (en) * | 1994-03-29 | 1995-10-05 | Edward B. Nelson | Treatment of atherosclerosis with angiotensin ii receptor blocking imidazoles |
| EP0914158B2 (de) * | 1996-04-05 | 2006-01-25 | Takeda Chemical Industries, Ltd. | Pharmazeutische kombination enthaltend einen wirkstoff mit angiotensin-ii antagonistischer aktivität und einen wirkstoff der die insulin-sensitivität erhöht |
| EP1514543A1 (de) | 1997-08-29 | 2005-03-16 | Pfizer Inc. | Kombinationstherapie, enthaltend Atorvastatin und blutdrucksenkendes Mittel |
| SI20305A (sl) | 1999-08-06 | 2001-02-28 | LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. | Kristali natrijeve soli pravastatina |
| GB0001662D0 (en) | 1999-02-06 | 2000-03-15 | Zeneca Ltd | Pharmaceutical compositions |
| AU2007200367B2 (en) * | 1999-02-06 | 2010-04-08 | Astrazeneca Ab | Use of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors for the manufacture of a medicament for the treatment of diabetic neuropathy |
| US6172441B1 (en) | 1999-06-28 | 2001-01-09 | Visteon Global Technologies, Inc. | Rotor assembly |
| DK1216038T3 (da) | 1999-08-30 | 2005-12-27 | Sanofi Aventis Deutschland | Anvendelse af inhibitorer af reninangiotensinsystemet ved forebyggelsen af cardiovaskulære hændelser |
| US6982251B2 (en) | 2000-12-20 | 2006-01-03 | Schering Corporation | Substituted 2-azetidinones useful as hypocholesterolemic agents |
| HU230253B1 (hu) | 2001-01-26 | 2015-11-30 | Merck Sharp & Dohme Corp | Peroxiszóma proliferátor-aktivált receptor (PPAR) aktivátor(ok) és szterin-abszorpció inhibitor(ok) kombinációi és alkalmazásuk vaszkuláris indikációk kezelésére |
| DK1355644T3 (da) | 2001-01-26 | 2006-10-23 | Schering Corp | Anvendelse af substituerede azetidinonforbindelser til behandling af sitosterolæmi |
| US7071181B2 (en) | 2001-01-26 | 2006-07-04 | Schering Corporation | Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors |
| US6576256B2 (en) | 2001-08-28 | 2003-06-10 | The Brigham And Women's Hospital, Inc. | Treatment of patients at elevated cardiovascular risk with a combination of a cholesterol-lowering agent, an inhibitor of the renin-angiotensin system, and aspirin |
| US6669955B2 (en) * | 2001-08-28 | 2003-12-30 | Longwood Pharmaceutical Research, Inc. | Combination dosage form containing individual dosage units of a cholesterol-lowering agent, an inhibitor of the renin-angiotensin system, and aspirin |
| US7053080B2 (en) | 2001-09-21 | 2006-05-30 | Schering Corporation | Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors |
| US7056906B2 (en) | 2001-09-21 | 2006-06-06 | Schering Corporation | Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women |
| JP2005504091A (ja) | 2001-09-21 | 2005-02-10 | シェーリング コーポレイション | ステロール吸収阻害剤としてアゼチジノンを用いる黄色腫の処置 |
| EP1501546B1 (de) * | 2002-05-03 | 2012-10-10 | Hexal AG | Stabile pharmazeutische formulierung für eine kombination aus einem statin mit einem ace-hemmer |
| AR040588A1 (es) | 2002-07-26 | 2005-04-13 | Schering Corp | Formulacion farmaceutica que comprende un inhibidor de la absorcion del colesterol y un inhibidor de una hmg- co a reductasa |
| WO2004043457A1 (en) | 2002-11-06 | 2004-05-27 | Schering Corporation | Cholesterol absorptions inhibitors for the treatment of autoimmune disorders |
| US7459442B2 (en) | 2003-03-07 | 2008-12-02 | Schering Corporation | Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof |
| CA2517571C (en) | 2003-03-07 | 2011-07-05 | Schering Corporation | Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof |
| JP2006519869A (ja) | 2003-03-07 | 2006-08-31 | シェーリング コーポレイション | 置換アゼチジノン化合物、置換アゼチジノン化合物を調製するためのプロセス、それらの処方物および使用 |
| JP4589919B2 (ja) | 2003-03-07 | 2010-12-01 | シェーリング コーポレイション | 高コレステロール血症の処置のための、置換アゼチジノン化合物、これらの処方物および使用 |
| WO2004085448A2 (en) * | 2003-03-19 | 2004-10-07 | Genzyme Corporation | Unsaturated phosphinyl-phosphonate phosphate transport inhibitors |
| GB0322552D0 (en) | 2003-09-26 | 2003-10-29 | Astrazeneca Uk Ltd | Therapeutic treatment |
| JP2012510511A (ja) * | 2008-12-01 | 2012-05-10 | インヴアスク セラピューテイックス インコーポレイテッド | レニン−アンジオテンシン−アルドステロン系阻害剤及びリポ酸化合物を含有する組成物、並びに、レニン−アンジオテンシン−アルドステロン系に関連した疾患の治療のためのそれらの使用 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3536687A1 (de) * | 1985-10-15 | 1987-04-16 | Hoechst Ag | Verfahren zur behandlung von atherosklerose, thrombose und der peripheren gefaesskrankheit |
-
1991
- 1991-04-19 CA CA002040865A patent/CA2040865C/en not_active Expired - Lifetime
- 1991-04-24 NZ NZ237929A patent/NZ237929A/en unknown
- 1991-04-26 AU AU76270/91A patent/AU651579B2/en not_active Expired
- 1991-04-29 IE IE143191A patent/IE77637B1/en not_active IP Right Cessation
- 1991-05-08 ZA ZA913509A patent/ZA913509B/xx unknown
- 1991-05-10 AT AT91304232T patent/ATE141514T1/de not_active IP Right Cessation
- 1991-05-10 DE DE69121464T patent/DE69121464T2/de not_active Expired - Lifetime
- 1991-05-10 EP EP91304232A patent/EP0457514B1/de not_active Expired - Lifetime
- 1991-05-10 DK DK91304232.1T patent/DK0457514T3/da active
- 1991-05-10 ES ES91304232T patent/ES2090244T3/es not_active Expired - Lifetime
- 1991-05-14 HU HU911620A patent/HU212102B/hu unknown
- 1991-05-14 KR KR1019910007749A patent/KR100200467B1/ko not_active Expired - Lifetime
- 1991-05-14 PT PT97660A patent/PT97660B/pt not_active IP Right Cessation
- 1991-05-15 JP JP3110268A patent/JPH04226921A/ja not_active Withdrawn
-
1996
- 1996-11-19 GR GR960403096T patent/GR3021703T3/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| DK0457514T3 (da) | 1996-09-16 |
| ZA913509B (en) | 1992-02-26 |
| GR3021703T3 (en) | 1997-02-28 |
| EP0457514B1 (de) | 1996-08-21 |
| HU212102B (en) | 1996-02-28 |
| AU651579B2 (en) | 1994-07-28 |
| KR910019614A (ko) | 1991-12-19 |
| NZ237929A (en) | 1997-06-24 |
| CA2040865A1 (en) | 1991-11-16 |
| DE69121464T2 (de) | 1997-03-27 |
| DE69121464D1 (de) | 1996-09-26 |
| HU911620D0 (en) | 1991-11-28 |
| EP0457514A1 (de) | 1991-11-21 |
| PT97660B (pt) | 1998-09-30 |
| HUT57993A (en) | 1992-01-28 |
| CA2040865C (en) | 2002-07-23 |
| KR100200467B1 (ko) | 1999-06-15 |
| PT97660A (pt) | 1992-02-28 |
| IE77637B1 (en) | 1997-12-31 |
| ES2090244T3 (es) | 1996-10-16 |
| JPH04226921A (ja) | 1992-08-17 |
| AU7627091A (en) | 1991-11-21 |
| IE911431A1 (en) | 1991-11-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE141514T1 (de) | Verfahren zur verhütung, stabilisierung oder verursachung des zurückgangs von atherosklerose durch anwendung einer mischung von einem cholesterol-vermindernden arzneimittel mit einem ace-inhibitor | |
| ATE244006T1 (de) | Verwendung eines hmg coa-reduktase inhibitors zur vorbeugung eines zweiten herzanfalls | |
| DE69128516D1 (de) | Neue Mercaptoacetylamid-Derivate zur Verwendung als Enkephalinase- und ACE-Hemmer | |
| DE59310377D1 (de) | Verfahren zur Nachprüfung von Sicherheitsabdrucken | |
| DE68918191D1 (de) | Verfahren zur Lactonisierung von Mevinsäuren und deren Analogen. | |
| DE69225128D1 (de) | Verfahren zur Aufbereitung von sich berührendem und degradiertem Text | |
| DE69428403D1 (de) | Verfahren zur Herstellung von Azetidinverbindungen und Ausgangsverbindungen dafür | |
| DE59402624D1 (de) | Verfahren zur Herstellung von Cycloolefincopolymeren | |
| DE69324689D1 (de) | Verwendung von diacylglycerolen zur steigerung des melaningehaltes in melanozyten | |
| DE69332732D1 (de) | Pharmazeutische Zusammensetzung und Methode zur Behandlung von Hyperlipidämie und Arterioskerose | |
| DE69324331D1 (de) | Verfahren zur Herstellung von Dialkylkarbonaten | |
| DE69306915D1 (de) | Kombination zur Detektion von Weichgewebeanomalien | |
| ATE142884T1 (de) | Verwendung von magnesium-pyridoxal-5'-phosphat- glutaminat zur verhinderung von krankheiten verursacht durch gefässläsionen | |
| DE69414361D1 (de) | Verfahren zur herstellung von acetanhydrid oder einer mischung von acetanhydrid und essigsäure | |
| DE59208936D1 (de) | Handstück zur stomatologischen Applikation von Laserlicht | |
| DE59302957D1 (de) | Verfahren zur Herstellung von Dialkylcarbonaten | |
| MD960168A (ro) | Metodă şi compuşi pentru tratamentul infecţiilor virale | |
| FI961380A7 (fi) | Koostumuksia virusten aiheuttamien kasvainten ehkäisemiseksi ja hoitam iseksi | |
| DE59300921D1 (de) | Verfahren zur Herstellung von beta-Hydroxycarbonsäureestern. | |
| DE59310153D1 (de) | Verfahren zur Herstellung von 4-Hydroxy-2.2.6.6-tetramethylpiperidin | |
| DE59404315D1 (de) | Verfahren zur Herstellung von Dialkylcarbonaten | |
| DE59408420D1 (de) | Niedrigviskose kosmetische und pharmazeutische emulsionen | |
| DE59402901D1 (de) | Verfahren zur Herstellung von 5-Fluoranthranilsäurealkylestern und/oder 5-Fluoranthranilsäure | |
| DE59010681D1 (de) | Strahlungsempfindliches Gemisch und Verfahren zur Herstellung von Reliefstrukturen | |
| DE59209484D1 (de) | Verfahren zur reinigung von gebrauchten schmierölen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification | ||
| EELA | Cancelled due to lapse of time |